Literature DB >> 6464668

Reduced binding of 3H-spiroperidol to lymphocyte in Wilson's disease.

A Członkowski, A Członkowska.   

Abstract

Biochemical studies of CSF from patients with Wilson's disease (WD) have increased that alterations in the state of dopaminergic and serotoninergic systems are similar to those manifested in Parkinson's disease. Recently, the density of dopaminergic receptors on lymphocytes has been found to be diminished in Parkinson's disease. In the present study, 3H-spiroperidol binding was evaluated in lymphocytes acquired from 12 patients suffering from WD, as compared to blood donors. A significant decrease in the number of binding sites (Bmax) was observed in the lymphocytes of the WD patients. There was no clear relationship between clinical status, age and duration of the disease and the alterations in receptor density. The mechanism underlying the decrease in lymphocyte 3H-spiroperidol binding sites in WD demands clarification.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6464668     DOI: 10.1111/j.1600-0404.1984.tb07816.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease.

Authors:  T Litwin; G Gromadzka; J Samochowiec; A Grzywacz; A Członkowski; A Członkowska
Journal:  JIMD Rep       Date:  2012-07-06

2.  mRNA expression of dopamine receptors in peripheral blood lymphocytes of computer game addicts.

Authors:  Nasim Vousooghi; Seyed Zeinolabedin Zarei; Mitra-Sadat Sadat-Shirazi; Fatemeh Eghbali; Mohammad Reza Zarrindast
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

3.  The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders.

Authors:  Francesca R Buttarelli; Alessandra Fanciulli; Clelia Pellicano; Francesco E Pontieri
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.